Cost-effectiveness modelling to optimise active screening strategy for gambiense human African trypanosomiasis in endemic areas of the Democratic Republic of Congo

Abstract Background Gambiense human African trypanosomiasis (gHAT) has been brought under control recently with village-based active screening playing a major role in case reduction. In the approach to elimination, we investigate how to optimise active screening in villages in the Democratic Republi...

Full description

Bibliographic Details
Main Authors: Christopher N. Davis, Kat S. Rock, Marina Antillón, Erick Mwamba Miaka, Matt J. Keeling
Format: Article
Language:English
Published: BMC 2021-04-01
Series:BMC Medicine
Subjects:
Online Access:https://doi.org/10.1186/s12916-021-01943-4
id doaj-993ff2081b384bd8804b9ca504ffc7b8
record_format Article
spelling doaj-993ff2081b384bd8804b9ca504ffc7b82021-04-04T11:28:36ZengBMCBMC Medicine1741-70152021-04-0119111810.1186/s12916-021-01943-4Cost-effectiveness modelling to optimise active screening strategy for gambiense human African trypanosomiasis in endemic areas of the Democratic Republic of CongoChristopher N. Davis0Kat S. Rock1Marina Antillón2Erick Mwamba Miaka3Matt J. Keeling4Mathematics Institute, University of WarwickMathematics Institute, University of WarwickSwiss Tropical and Public Health InstituteProgramme National de Lutte contre la Trypanosomiase Humaine Africaine (PNLTHA)Mathematics Institute, University of WarwickAbstract Background Gambiense human African trypanosomiasis (gHAT) has been brought under control recently with village-based active screening playing a major role in case reduction. In the approach to elimination, we investigate how to optimise active screening in villages in the Democratic Republic of Congo, such that the expenses of screening programmes can be efficiently allocated whilst continuing to avert morbidity and mortality. Methods We implement a cost-effectiveness analysis using a stochastic gHAT infection model for a range of active screening strategies and, in conjunction with a cost model, we calculate the net monetary benefit (NMB) of each strategy. We focus on the high-endemicity health zone of Kwamouth in the Democratic Republic of Congo. Results High-coverage active screening strategies, occurring approximately annually, attain the highest NMB. For realistic screening at 55% coverage, annual screening is cost-effective at very low willingness-to-pay thresholds (<DOLLAR/>20.4 per disability adjusted life year (DALY) averted), only marginally higher than biennial screening (<DOLLAR/>14.6 per DALY averted). We find that, for strategies stopping after 1, 2 or 3 years of zero case reporting, the expected cost-benefits are very similar. Conclusions We highlight the current recommended strategy—annual screening with three years of zero case reporting before stopping active screening—is likely cost-effective, in addition to providing valuable information on whether transmission has been interrupted.https://doi.org/10.1186/s12916-021-01943-4African trypanosomiasisAfrican sleeping sicknessMathematical modelCost-effectiveness
collection DOAJ
language English
format Article
sources DOAJ
author Christopher N. Davis
Kat S. Rock
Marina Antillón
Erick Mwamba Miaka
Matt J. Keeling
spellingShingle Christopher N. Davis
Kat S. Rock
Marina Antillón
Erick Mwamba Miaka
Matt J. Keeling
Cost-effectiveness modelling to optimise active screening strategy for gambiense human African trypanosomiasis in endemic areas of the Democratic Republic of Congo
BMC Medicine
African trypanosomiasis
African sleeping sickness
Mathematical model
Cost-effectiveness
author_facet Christopher N. Davis
Kat S. Rock
Marina Antillón
Erick Mwamba Miaka
Matt J. Keeling
author_sort Christopher N. Davis
title Cost-effectiveness modelling to optimise active screening strategy for gambiense human African trypanosomiasis in endemic areas of the Democratic Republic of Congo
title_short Cost-effectiveness modelling to optimise active screening strategy for gambiense human African trypanosomiasis in endemic areas of the Democratic Republic of Congo
title_full Cost-effectiveness modelling to optimise active screening strategy for gambiense human African trypanosomiasis in endemic areas of the Democratic Republic of Congo
title_fullStr Cost-effectiveness modelling to optimise active screening strategy for gambiense human African trypanosomiasis in endemic areas of the Democratic Republic of Congo
title_full_unstemmed Cost-effectiveness modelling to optimise active screening strategy for gambiense human African trypanosomiasis in endemic areas of the Democratic Republic of Congo
title_sort cost-effectiveness modelling to optimise active screening strategy for gambiense human african trypanosomiasis in endemic areas of the democratic republic of congo
publisher BMC
series BMC Medicine
issn 1741-7015
publishDate 2021-04-01
description Abstract Background Gambiense human African trypanosomiasis (gHAT) has been brought under control recently with village-based active screening playing a major role in case reduction. In the approach to elimination, we investigate how to optimise active screening in villages in the Democratic Republic of Congo, such that the expenses of screening programmes can be efficiently allocated whilst continuing to avert morbidity and mortality. Methods We implement a cost-effectiveness analysis using a stochastic gHAT infection model for a range of active screening strategies and, in conjunction with a cost model, we calculate the net monetary benefit (NMB) of each strategy. We focus on the high-endemicity health zone of Kwamouth in the Democratic Republic of Congo. Results High-coverage active screening strategies, occurring approximately annually, attain the highest NMB. For realistic screening at 55% coverage, annual screening is cost-effective at very low willingness-to-pay thresholds (<DOLLAR/>20.4 per disability adjusted life year (DALY) averted), only marginally higher than biennial screening (<DOLLAR/>14.6 per DALY averted). We find that, for strategies stopping after 1, 2 or 3 years of zero case reporting, the expected cost-benefits are very similar. Conclusions We highlight the current recommended strategy—annual screening with three years of zero case reporting before stopping active screening—is likely cost-effective, in addition to providing valuable information on whether transmission has been interrupted.
topic African trypanosomiasis
African sleeping sickness
Mathematical model
Cost-effectiveness
url https://doi.org/10.1186/s12916-021-01943-4
work_keys_str_mv AT christopherndavis costeffectivenessmodellingtooptimiseactivescreeningstrategyforgambiensehumanafricantrypanosomiasisinendemicareasofthedemocraticrepublicofcongo
AT katsrock costeffectivenessmodellingtooptimiseactivescreeningstrategyforgambiensehumanafricantrypanosomiasisinendemicareasofthedemocraticrepublicofcongo
AT marinaantillon costeffectivenessmodellingtooptimiseactivescreeningstrategyforgambiensehumanafricantrypanosomiasisinendemicareasofthedemocraticrepublicofcongo
AT erickmwambamiaka costeffectivenessmodellingtooptimiseactivescreeningstrategyforgambiensehumanafricantrypanosomiasisinendemicareasofthedemocraticrepublicofcongo
AT mattjkeeling costeffectivenessmodellingtooptimiseactivescreeningstrategyforgambiensehumanafricantrypanosomiasisinendemicareasofthedemocraticrepublicofcongo
_version_ 1721542756322508800